Results of Operations and Financial Condition. On August 12, 2026, STAAR Surgical Company (the “Company”) published a press release reporting its financial results for the quarter ended July 3, 2026, a copy of which is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.

CEO — Warren Foust: Warren Foust was promoted to President and CEO.

The filing pertains to the approval of an equity incentive plan amendment, not a management change.

Interim Co-Chief Executive Officer and Chief Financial Officer — Deborah Andrews: Compensation increase for Deborah Andrews in recognition of her contributions and competitive market data.

Results of Operations and Financial Condition. On May 13, 2026, STAAR Surgical Company (the “Company”) published a press release reporting its financial results for the quarter ended April 3, 2026, a copy of which is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.

Results of Operations and Financial Condition. On March 3, 2026, STAAR Surgical Company (the “Company”) published a press release reporting its financial results for the quarter and year ended January 2, 2026, a copy of which is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.

Chief Legal Officer and Corporate Secretary — Nathaniel Sisitsky: Mr. Sisitsky's employment was terminated without cause, with a consulting agreement for transition support.

Chief Executive Officer — Stephen C. Farrell: Stephen C. Farrell stepped down as Chief Executive Officer, and the company appointed Warren Foust and Deborah Andrews as Interim Co-Chief Executive Officers.

Board Chair — Neal C. Bradsher: The filing reports the election of a new Board Chair and committee reorganization, with no indication of a sitting executive's departure.

CEO — Stephen C. Farrell: The CEO is terminating his employment and board seat in connection with a cooperation agreement, representing a significant loss of senior leadership.

of this Current Report on Form 8-K is incorporated herein by reference. Messrs. Bradsher, LeBuhn and Wang will receive the standard director compensation for a non-employee director, pro-rated for the remaining portion of the 2025-2026 term. Additionally, in connection with the appointment of Messrs. Bradsher, LeBuhn and Wang to the Board, the Company, on one hand, and Messrs. Bradsher, LeBuhn and Wang, on the other hand, are expected to enter into an indemnification agreement in substantiall…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As discussed further below, on January 14, 2026, Elizabeth Yeu, MD resigned from the Board. Among other things, NASDAQ Listing Rule 5605 requires listed issuers such as the Company to maintain an audit committee consisting of no fewer than three independent directors. Dr. Yeu had been one of three independent directors on the Company’s Audit Committee at the time of her resignation, and theref…

Termination of a Material Definitive Agreement. As previously disclosed, on August 4, 2025, STAAR Surgical Company (the “Company”) entered into an Agreement and Plan of Merger, dated as of August 4, 2025 (as amended, the “Merger Agreement”), by and among the Company, Alcon Research, LLC (“Alcon”) and Rascasse Merger Sub, Inc. (“Merger Sub”), pursuant to which the parties agreed that Merger Sub would merge with and into the Company, subject to the satisfaction or waiver of the conditions set f…

Entry into a Material Definitive Agreement. On December 9, 2025, STAAR Surgical Company (the “Company”) entered into Amendment No. 2 (the “Amendment”) to the Agreement and Plan of Merger, dated August 4, 2025 (as amended, the “Amended Merger Agreement”), with Alcon Research, LLC (“Alcon”) and Rascasse Merger Sub, Inc. (“Merger Sub”). The Amendment, among other things, increases the consideration to be paid to the holders of shares of common stock, par value $0.01 per share, of the Company (“C…

Entry into a Material Definitive Agreement. On November 7, 2025, STAAR Surgical Company (the “Company”) entered into Amendment No. 1 (the “Amendment”) to the Agreement and Plan of Merger, dated August 4, 2025 (the “Merger Agreement” and as amended by the Amendment, the “Amended Merger Agreement”), with Alcon Research, LLC (“Alcon”) and Rascasse Merger Sub, Inc. (“Merger Sub”). The Amendment provides that from November 7, 2025 until 11:59 p.m. (Eastern Time) on December 6, 2025 (the “go-shop p…

Results of Operations and Financial Condition. On November 5, 2025, STAAR Surgical Company (the “Company”) published a press release reporting its financial results for the quarter ended September 26, 2025, a copy of which is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference. The information furnished herewith pursuant to

Results of Operations and Financial Condition. On October 20, 2025, STAAR Surgical Company (the “Company”) published a press release reporting its preliminary net sales results for the quarter ended September 26, 2025, a copy of which is filed as Exhibit 99.1 to this report and is incorporated herein by this reference.

Other Events. As previously disclosed, on August 4, 2025, STAAR Surgical Company (“STAAR”), Alcon Research, LLC (“Alcon”) and Rascasse Merger Sub, Inc., a wholly owned subsidiary of Alcon (“Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which, among other things and subject to the terms and conditions therein, Merger Sub will merge with and into STAAR, with STAAR surviving the merger as a direct, wholly owned subsidiary of Alcon (such transact…

Results of Operations and Financial Condition. On August 6, 2025, STAAR Surgical Company (the “Company”) published a press release reporting its financial results for the quarter ended June 27, 2025, a copy of which is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference. The information furnished herewith pursuant to

Entry into a Material Definitive Agreement. On August 4, 2025, STAAR Surgical Company, a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Alcon Research, LLC, a Delaware limited liability company (“Alcon”), and Rascasse Merger Sub, Inc., a Delaware corporation and a wholly owned direct subsidiary of Alcon (“Merger Sub”). The Merger Agreement provides, among other things, that subject to the satisfaction or waiver of the condition…

CFO — Deborah Andrews: The filing announces the appointment of a former CFO as the permanent CFO, which is a significant executive hire rather than a departure.

Other Events. Share Repurchase Authorization On May 16, 2025, STAAR Surgical Company (the “Company”) issued a press release announcing that its Board of Directors had authorized a share repurchase program under which the Company may repurchase up to $30 million of its outstanding common stock. Under the program, the Company may repurchase shares in the open market, through privately negotiated transactions, by entering into structured repurchase agreements with third parties, by making block…

Results of Operations and Financial Condition. On May 7, 2025, STAAR Surgical Company (the “Company”) published a press release reporting its financial results for the quarter ended March 28, 2025, a copy of which is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.

Director — Louis E. Silverman: The filing discloses the appointment of a returning director and the non-re-election of another, which are standard board composition changes rather than executive departures.

CFO — Patrick Williams: The CFO was removed from his position at the request of the Board, which indicates a forced departure or termination for cause rather than a routine succession.